Literature DB >> 17951917

Enterobacter endophthalmitis: treatment with intravitreal tazobactam - piperacillin.

Trehan Hemant Singh, Avinash Pathengay, Taraprasad Das, Savitri Sharma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951917      PMCID: PMC2635989          DOI: 10.4103/0301-4738.36495

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Dear Editor, Traumatic endophthalmitis is not uncommon following hypodermic needle injury and is associated with severe ocular morbidity.1,2 Enterobacter is a ubiquitous gram-negative bacillus rarely associated with endophthalmitis. We report the first case of multi-drug-resistant endophthalmitis caused by Enterobacter species treated with intravitreal piperacillin and tazobactam (Medline Search). A 25-year-old male presented with pain, redness and diminished vision of two days duration following iatrogenic injury to his left eye by a hypodermic needle. Best corrected visual acuity (BCVA) was 20/20 in right eye and perception of light with accurate projection of light rays in the left eye. On examination, a self-sealed scleral laceration was noted near the temporal limbus of the left eye. Hypopyon with fibrinous pupillary membrane noted in the anterior chamber obscured view of the fundus. Ultrasonography showed multiple low reflective vitreous membranes with after movements. A diagnosis of post-traumatic endophthalmitis was made and the patient underwent pars plana lensectomy, vitrectomy and intraocular antibiotic injection of vancomycin 1 mg / 0.1 ml and amikacin 400 µgm / 0.1 ml. The patient was treated with ciprofloxacin eye drops and betamethasone eye drops hourly and cyclopentolate eye drops thrice daily. Oral ciprofloxacin 750 mg twice a day and oral prednisolone 70 mg /day (1 mg/kg) were also administered. The right eye was normal. Enterobacter spp. isolated from vitreous and identified by API 20 E (bioMιrieux, France) on the third postoperative day was resistant to vancomycin, amikacin, ceftazidime, ciprofloxacin, gatifloxacin, chloramphenicol and cefazolin by Kirby Bauer disc diffusion method. Since there was no improvement clinically and the isolated organism was resistant to intravitreally administered antibiotics, he was injected intravitreally, combination of tazobactam and piperacillin (225 µgm /0.1 ml) based on available experimental data.3,4 Systemic corticosteroids were continued and ciprofloxacin was discontinued. Four days after the intravitreal injection, vitritis decreased with BCVA improving to 20/80. At one month BCVA was 20/40 with resolution of vitritis. Enterobacter spp. develop resistance rapidly to antibiotics due to their capacity to produce extended spectrum beta-lactamases.5 Piperacillin and tazobactam complement in their mechanism of action against beta-lactamase-producing organisms. Due to the production of high levels of beta-lactamase, combination therapy with piperacillin and tazobactam is a safe and effective alternative in the management of multi-drug-resistant gram-negative infections.6,7 To conclude, intravitreal injection of piperacillin and tazobactam could be effective in the management of multi-drug-resistant endophthalmitis caused by gram-negative bacteria.
  7 in total

1.  The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.

Authors:  Abdullah Ozkiris; Cem Evereklioglu; Duygu Esel; Hülya Akgün; Sertan Göktas; Kuddusi Erkiliç
Journal:  Curr Eye Res       Date:  2005-01       Impact factor: 2.424

Review 2.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Hypodermic needles: a new source of penetrating ocular trauma in Indian children.

Authors:  S Jalali; T Das; A B Majji
Journal:  Retina       Date:  1999       Impact factor: 4.256

4.  Relationship between clinical presentation and visual outcome in postoperative and posttraumatic endophthalmitis in south central India.

Authors:  Taraprasad Das; Derek Y Kunimoto; Savitri Sharma; Subhadra Jalali; Ajit B Majji; T Nagaraja Rao; Usha Gopinathan; Sreedharan Athmanathan
Journal:  Indian J Ophthalmol       Date:  2005-03       Impact factor: 1.848

5.  Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.

Authors:  Srujana Mohanty; Ritu Singhal; Seema Sood; Benu Dhawan; Bimal K Das; Arti Kapil
Journal:  Indian J Med Res       Date:  2005-11       Impact factor: 2.375

6.  Determination of nontoxic concentrations of piperacillin/tazobactam for intravitreal application. An electroretinographic, histopathologic and morphometric analysis.

Authors:  Abdullah Ozkiriş; Cem Evereklioglu; Olgun Kontaş; Ayşe Oztürk Oner; Kuddusi Erkiliç
Journal:  Ophthalmic Res       Date:  2004 May-Jun       Impact factor: 2.892

7.  Enterobacter bacteremia.

Authors:  N Gupta; Uma Choudhary; Nidhi Garg; D R Arora
Journal:  J Assoc Physicians India       Date:  2003-07
  7 in total
  4 in total

Review 1.  Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature.

Authors:  Neha Goel; Vishaal Bhambhwani; Basudeb Ghosh
Journal:  Int Ophthalmol       Date:  2015-06-03       Impact factor: 2.031

Review 2.  Pharmacokinetics of intravitreal antibiotics in endophthalmitis.

Authors:  Medikonda Radhika; Kopal Mithal; Abhishek Bawdekar; Vivek Dave; Animesh Jindal; Nidhi Relhan; Thomas Albini; Avinash Pathengay; Harry W Flynn
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-09-10

3.  Enterobacter endophthalmitis: Clinical settings, susceptibility profile, and management outcomes across two decades.

Authors:  Vivek Pravin Dave; Avinash Pathengay; Shashwat Behera; Joveeta Joseph; Savitri Sharma; Rajeev Reddy Pappuru; Taraprasad Das
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

4.  Commentary: Enterobacter endophthalmitis: Clinical settings, susceptibility profile, and management outcomes across two decades.

Authors:  Chitaranjan Mishra; Kim Ramasamy
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.